Given Imaging Ltd. (NASDAQ: GIVN), a world leader in specialty GI
products and pioneer of capsule endoscopy, today announced that
employees in its Duluth, Georgia, and Los Angeles, California,
offices dressed in blue in support of the national awareness
initiative promoted by the Colon Cancer Alliance. The Dress in Blue
Day and proud display of the Blue Star, a symbol representing the
fight against colorectal cancer, kick off a series of activities
the company initiated in support of Colorectal Cancer Awareness
Month.
Next week, Given Imaging will send a small group of employees to
Washington, D.C., to "Call on Congress" in an effort to fight
colorectal cancer, the second-leading cause of cancer deaths in
America. The event will help train colorectal cancer advocates --
patients, survivors and caregivers -- on how to create open and
effective discourse about this deadly disease with their elected
officials. On the second day of the event, attendees will take
their learnings to the halls of Congress, armed with colorectal
cancer information, state-specific statistics, and a call to action
to support colorectal cancer legislation that will save money and
save lives. Given Imaging is a sponsor of the final event of the
Call on Congress, the Colorectal Cancer Coalition's Annual Advocacy
Dinner Celebration. To learn more about the Colorectal Cancer
Coalition's Call on Congress Day 2011, please visit:
http://fightcolorectalcancer.org/policy/call-on_congress.
Additionally, Given Imaging has created a free interactive
e-card for people turning fifty years old to encourage routine
colorectal cancer screening. The e-card incorporates the Blue Star,
and is available by visiting www.AndManyMore.org.
"Colorectal cancer is often a preventable disease when detected
early. We at Given Imaging want to support these important patient
organizations, such as Colorectal Cancer Coalition and Colon Cancer
Alliance, that do so much to raise awareness and fight this
important battle," said Homi Shamir, president and chief executive
officer, Given Imaging Ltd.
About Colorectal Cancer Colorectal cancer
remains a potentially fatal disease that generally can be prevented
through early detection. Colon cancer occurs in the large intestine
(colon), the lower part of the digestive system, while rectal
cancer occurs in the last 15-20 centimeters of the colon. Together,
they're often referred to as colorectal cancers.
Colon and rectal cancers begin in the digestive system and
develop when cells that line the colon or the rectum become
abnormal and grow exponentially. Most cases of colorectal cancer
begin as small, non-cancerous (benign) clumps of cells called
adenomatous polyps. Only certain kinds of polyps have the potential
to become cancerous, and in most people, colorectal cancers develop
slowly over a period of several years. In the US alone, more than
51,000 people will die from colorectal cancer in 2010(1).
About the Blue Star Introduced on April 1,
2004, by the National Colorectal Cancer Roundtable (NCCRT), the
Blue Star symbol represents the fight against colorectal
cancer.
The Blue Star has already been adopted by nearly all of the
major groups in the colorectal cancer community, symbolizing their
united effort in the battle to prevent colorectal cancer deaths.
The star represents the eternal memory of the people whose lives
have been lost to the disease and the shining hope for a future
free of colorectal cancer. The star, merged with a ribbon to
represent increased awareness, assumes a human shape.
The Blue Star raises awareness about how to prevent colorectal
cancer, the nation's third-leading cause of cancer death in both
men and women. The NCCRT encourages organizations to incorporate
the Blue Star and the universal message that colorectal cancer is
preventable, treatable, and beatable into their communications and
awareness efforts. For more information please visit:
www.bluestarforcoloncancer.org.
About Given Imaging Ltd.
Since 2001, Given Imaging has advanced gastrointestinal
visualization by developing state-of-the art, patient-friendly
tools based on its PillCam® Platform. PillCam® capsule endoscopy
uses wireless technology and advanced software to provide
physicians with clear images of the small intestine via PillCam® SB
and the esophagus through PillCam® ESO. The PillCam® capsules are
miniature video cameras that patients ingest. Given Imaging's other
capsule products include Agile™ patency capsule, to verify
intestinal patency, and Bravo® , the only wireless, catheter-free,
48-hour pH test commercially available for pH testing to assess
gastroesophageal reflux disease (GERD). In April, 2010, Given
Imaging acquired Sierra Scientific Instruments, the leading
provider of specialty GI diagnostic solutions and pioneer of
high-resolution manometry for assessing gastrointestinal motility.
Sierra Scientific is now a wholly-owned subsidiary of Given
Imaging. Given Imaging's headquarters, manufacturing and R&D
facilities are located in Yoqneam, Israel, with operating
subsidiaries in the United States, Germany, France, Japan,
Australia, and Hong Kong. For more information, please visit
www.givenimaging.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, projections about our
business and our future revenues, expenses and profitability.
Forward-looking statements may be, but are not necessarily,
identified by the use of forward-looking terminology such as
"will," "may," "anticipates," "estimates," "expects," "intends,"
"plans," "believes," and words and terms of similar substance.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual events,
results, performance, circumstances or achievements of the Company
to be materially different from any future events, results,
performance, circumstances or achievements expressed or implied by
such forward-looking statements. Factors that could cause actual
events, results, performance, circumstances or achievements to
differ from such forward-looking statements include, but are not
limited to, the following: (1) our ability to develop and bring to
market new products, (2) our ability to successfully complete any
necessary or required clinical studies with our products, (3) our
ability to receive regulatory clearance or approval to market our
products or changes in regulatory environment, (4) our success in
implementing our sales, marketing and manufacturing plans, (5) the
level of adoption of our products by medical practitioners, (6) the
emergence of other products that may make our products obsolete,
(7) lack of an appropriate bowel preparation materials to be used
with our PillCam COLON capsule, (8) protection and validity of
patents and other intellectual property rights, (9) the impact of
currency exchange rates, (10) the effect of competition by other
companies, (11) the outcome of significant litigation, (12) the
availability of reimbursement or other forms of funding for our
products from government and commercial payors, (13) quarterly
variations in operating results, (14) the possibility of armed
conflict or civil or military unrest in Israel, (15) the impact of
global economic conditions, (16) our ability to successfully
integrate acquired businesses, (17) changes and reforms in
applicable healthcare laws and regulations, and (18) other risks
and factors disclosed in our filings with the U.S. Securities and
Exchange Commission, including, but not limited to, risks and
factors identified under such headings as "Risk Factors,"
"Cautionary Language Regarding Forward-Looking Statements" and
"Operating Results and Financial Review and Prospects" in the
Company's Annual Report on Form 20-F for the year ended December
31, 2009. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Except for the Company's ongoing obligations to
disclose material information under the applicable securities laws,
it undertakes no obligation to release publicly any revisions to
any forward-looking statements, to report events or to report the
occurrence of unanticipated events.
(1)
http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics
Image Available:
http://www2.marketwire.com/mw/frame_mw?attachid=1534403 Image
Available:
http://www2.marketwire.com/mw/frame_mw?attachid=1534400
For further information contact: Fern Lazar/David Carey
Lazar Partners Ltd. 212-867-1768 Email Contact Email Contact
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024